<DOC>
	<DOCNO>NCT02293356</DOCNO>
	<brief_summary>This clinical study design open , single group , multi-center , phase 4 clinical study ass safety Nimotuzumab treatment nasopharyngeal carcinoma provide reasonable basis clinical drug program .</brief_summary>
	<brief_title>Phase IV Clinical Trial Nimotuzumab Treatment Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>This clinical study design open , single group , multi-center , phase 4 clinical study ass safety Nimotuzumab treatment nasopharyngeal carcinoma provide reasonable basis clinical drug program . Subjects meet inclusion/exclusion criterion administer Nimotuzumab base medication instruction adjust clinician accord treatment . In case progression disease , unacceptable toxicity , withdrawal consent , judgment investigator treatment need stop , treatment Nimotuzumab stop .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>1 . Patients histologically cytologically confirm nasopharyngeal carcinoma 2 . Sex age without limit 3 . Treatment without limit 4 . Subjects reproductive potential ( male female ) willing use reliable mean contraception 5 . Able willing give write informed consent comply requirement study protocol 1 . Patients severe allergy idiosyncratic constitution 2 . Women pregnant ( determined urine pregnancy test ) breast feed 3 . Any severe complication functional disorder organ system , affect evaluation safety patient interfere test drug accord researcher 's point view</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>